Deals and Financings

Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.

The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.

Abbott and Bigfoot Biomedical have worked as partners for more than half a decade but will now continue as one. Analysts are questioning whether the merger will simply be a tuck-in for Abbott, or enable it to release an insulin pump of their own.

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights VR, AI and other high tech trends in rehabilitation and gait training. Hannah Daniel discusses cybersecurity updates such as the new NIST published draft for an updated version of the Cybersecurity Framework, a recent report by Health-ISAC, and an interview with MedCrypt’s Naomi Schwartz about the upcoming FDA cybersecurity regulations for premarket approvals.

After receiving US FDA clearance in May, Beta Bionics secured $100m in financing which is expected to be used to commercialize its iLet Bionic Pancreas and “further develop and test the bi-hormonal bionic pancreas.”

3M will pay out more than $15bn in settlements reached this year after agreeing to a $6bn settlement over its ear defenders.

After a summer of speculation about who will close the deal with Abcam, tech leader Danaher came out ahead and will acquire Abcam for $24 a share.

Ivan Tornos will shift from COO to CEO of Zimmer Biomet now that former CEO Bryan Hanson has accepted the CEO job at 3M’s health care spinoff.

Exor’s CEO John Elkann said the company is committed to supporting Philips’ “change of path” to combine health care and technology. 

ReWalk Robotics’ planned $19m acquisition of AlterG will put ReWalk on the path to profitability and positive cash flow, creating a combined company with trailing 12-month revenues of about $26m.

The heart tech company plans to use the new funding to test its robotics- and catheter-based solution for treating mitral and tricuspid valve disease in humans.

Cooper announced a plan to buy Cook’s reproductive health business in February. The deal would have been worth $675m up front and $200m in four annual installments. The US FTC determined the deal would have impaired competition in the reproductive health market.

A jump in earnings, the acquisition of Apton and the launch of the long-awaited Onso sequencing system – all in one week at Pacific Biosciences.

Surgalign was forced into bankruptcy after falling foul of the US SEC, leaving Audmedics to pick up its digital health assets for the bargain price of $900,000.

This week, Abiomed announced a class I recall of Impella heart pumps; the FDA released new device sterilization standards; and Boston Scientific planned a $140m new campus in Minnesota.

Teleflex markets the UroLift minimally invasive system for managing symptomatic benign prostate hyperplasia. Palette sells five urology products, including Barrigel spacer gel for prostate radiotherapy.